171 related articles for article (PubMed ID: 32455341)
1. Identifying outcomes that are important to patients with ocular hypertension or primary open-angle glaucoma: a qualitative interview study.
Le JT; Mohanty K; Bicket AK; Tarver ME; Eydelman M; Li T
Ophthalmol Glaucoma; 2019; 2(6):374-382. PubMed ID: 32455341
[TBL] [Abstract][Full Text] [Related]
2. Priorities and Treatment Preferences among Surgery-Naive Patients with Moderate to Severe Open-Angle Glaucoma.
Bicket AK; Le JT; Yorkgitis C; Li T
Ophthalmol Glaucoma; 2020; 3(5):377-383. PubMed ID: 32768363
[TBL] [Abstract][Full Text] [Related]
3. Prioritizing outcome preferences in patients with ocular hypertension and open-angle glaucoma using best-worst scaling.
Le JT; Bicket AK; Janssen EM; Grover D; Radhakrishnan S; Vold S; Tarver ME; Eydelman M; Bridges JFP; Li T
Ophthalmol Glaucoma; 2019; 2(6):367-373. PubMed ID: 32355909
[TBL] [Abstract][Full Text] [Related]
4. Intraocular pressure changes following topical ocular hypotensive medications washout.
Ho H; Daas A; Ho J; Alaghband P; Galvis EA; de Antonio Ramirez A; Grassi P; Lim R; Lim KS
Br J Ophthalmol; 2021 Feb; 105(2):205-209. PubMed ID: 32277009
[TBL] [Abstract][Full Text] [Related]
5. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
Kass MA; Heuer DK; Higginbotham EJ; Johnson CA; Keltner JL; Miller JP; Parrish RK; Wilson MR; Gordon MO
Arch Ophthalmol; 2002 Jun; 120(6):701-13; discussion 829-30. PubMed ID: 12049574
[TBL] [Abstract][Full Text] [Related]
6. The Effectiveness and Safety of Micropulse Cyclophotocoagulation in the Treatment of Ocular Hypertension and Glaucoma.
Kaba Q; Somani S; Tam E; Yuen D
Ophthalmol Glaucoma; 2020; 3(3):181-189. PubMed ID: 32672613
[TBL] [Abstract][Full Text] [Related]
7. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data: A Secondary Analysis of 2 Randomized Clinical Trials.
Gordon MO; Gao F; Huecker JB; Miller JP; Margolis M; Kass MA; Miglior S; Torri V;
JAMA Ophthalmol; 2020 Jul; 138(7):780-788. PubMed ID: 32496526
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
10. Primary open-angle glaucoma in a population associated with high prevalence of primary angle-closure glaucoma: the Kumejima Study.
Yamamoto S; Sawaguchi S; Iwase A; Yamamoto T; Abe H; Tomita G; Tomidokoro A; Araie M
Ophthalmology; 2014 Aug; 121(8):1558-65. PubMed ID: 24746386
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis.
Li F; Huang W; Zhang X
Acta Ophthalmol; 2018 May; 96(3):e277-e284. PubMed ID: 29144028
[TBL] [Abstract][Full Text] [Related]
12. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
[TBL] [Abstract][Full Text] [Related]
13. Long-term evaluation of ocular hypertension with primary angle closure and primary open angles.
Sihota R; Selvan H; Sharma A; Gupta A; Gupta V; Dada T; Upadhyay AD
Int Ophthalmol; 2019 Apr; 39(4):803-812. PubMed ID: 29508190
[TBL] [Abstract][Full Text] [Related]
14. The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics.
Konstantakopoulou E; Gazzard G; Vickerstaff V; Jiang Y; Nathwani N; Hunter R; Ambler G; Bunce C;
Br J Ophthalmol; 2018 May; 102(5):599-603. PubMed ID: 28982956
[TBL] [Abstract][Full Text] [Related]
15. Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication.
King AJ; Rotchford AP
JAMA Ophthalmol; 2016 Jul; 134(7):742-7. PubMed ID: 27148831
[TBL] [Abstract][Full Text] [Related]
16. Relationship of intraocular pressure and frequency of spontaneous retinal venous pulsation in primary open-angle glaucoma.
Seo JH; Kim TW; Weinreb RN; Kim YA; Kim M
Ophthalmology; 2012 Nov; 119(11):2254-60. PubMed ID: 22980741
[TBL] [Abstract][Full Text] [Related]
17. Twenty-four-hour pattern of intra-ocular pressure in untreated patients with primary open-angle glaucoma.
Cheng J; Kong X; Xiao M; Sun X
Acta Ophthalmol; 2016 Sep; 94(6):e460-7. PubMed ID: 26843038
[TBL] [Abstract][Full Text] [Related]
18. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
Gazzard G; Konstantakopoulou E; Garway-Heath D; Garg A; Vickerstaff V; Hunter R; Ambler G; Bunce C; Wormald R; Nathwani N; Barton K; Rubin G; Morris S; Buszewicz M
Health Technol Assess; 2019 Jun; 23(31):1-102. PubMed ID: 31264958
[TBL] [Abstract][Full Text] [Related]
19. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
Diestelhorst M
Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial.
Gagliano C; Ortisi E; Pulvirenti L; Reibaldi M; Scollo D; Amato R; Avitabile T; Longo A
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):6096-100. PubMed ID: 21705689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
